Pharmacy Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Clinical Pharmacy Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium.
J Clin Pharm Ther. 2021 Jun;46(3):738-743. doi: 10.1111/jcpt.13339. Epub 2021 Mar 25.
Prescribing errors are the leading cause of adverse drug events in hospitalized patients. Pharmaceutical validation, defined as the review of drug orders by a pharmacist, associated with clinical decision support (CDS) systems, significantly reduces these errors and adverse drug events. In Belgium, because clinical pharmacy services have limited public financial support, most pharmaceutical validations are performed at the central pharmacy instead of on-ward, by hospital pharmacists doing dispensing activities. In that context, we aimed at evaluating whether the strategy of CDS-guided central validation was the most appropriate method to improve the quality and safety of medicines' use compared to an on-ward pharmaceutical validation.
Our retrospective observational study was conducted in a Belgian tertiary care hospital, in 2018-2019. Data were extracted from our validation software and pharmacists' charts. The outcomes of the study were the number of pharmaceutical interventions due to the detection of prescribing errors, reasons for interventions, their acceptance rate and their potential clinical impact (according to two blinded experts) in the central pharmacy and on-ward validation groups.
Despite the use of the same CDS, a pharmaceutical intervention following the detection of a prescribing error was made for 2.9% (20/698) of central group patients and 13.3% (93/701) of on-ward patients (χ = 49.97, p < 0.001). Interventions made at the central pharmacy (n = 20) mostly relied on CDS-alerts (i.e. drug-drug interaction [25%] or overdosing [20%]) while interventions made on-ward (n = 93) were also for pharmacotherapy optimization (i.e. no valid indication [25%] or inappropriate drug's choice [11%]). The on-ward validation group showed a higher acceptance rate compared to the central group (84% and 65%, respectively [Fisher's test, p = 0.053]). Proportions of interventions with significant or very significant clinical impact were similar between the two groups but as fewer interventions were made centrally, a significant proportion of errors were probably not detected by the central validation.
On-ward pharmaceutical validation leads to a higher rate of prescribing error detection. Pharmaceutical interventions made by on-ward pharmacists are also better accepted and more relevant, going further than CDS-alerts.
处方错误是住院患者发生药物不良事件的主要原因。药物验证(由药剂师审查药物医嘱,并与临床决策支持系统相关联)可显著减少这些错误和药物不良事件。在比利时,由于临床药学服务的公共财政支持有限,大多数药物验证都是由中央药房的医院药剂师在药房发药活动之外进行的。在这种情况下,我们旨在评估与在病房进行药物验证相比,以临床决策支持系统为指导的中央验证策略是否是提高药物使用质量和安全性的最合适方法。
我们的回顾性观察性研究在 2018 年至 2019 年期间在比利时一家三级保健医院进行。数据从我们的验证软件和药剂师图表中提取。研究的结果是在中央药房和病房药物验证组中,由于检测到处方错误而进行的药物干预数量、干预原因、接受率及其潜在的临床影响(根据两名盲法专家)。
尽管使用了相同的临床决策支持系统,但在中央组患者中,由于检测到处方错误而进行药物干预的比例为 2.9%(20/698),而在病房组患者中为 13.3%(93/701)(χ²=49.97,p<0.001)。在中央药房进行的干预主要依赖于临床决策支持系统警报(即药物相互作用[25%]或过量[20%]),而在病房进行的干预也是为了优化药物治疗(即无有效指征[25%]或药物选择不当[11%])。与中央组相比,病房组的接受率更高(分别为 84%和 65%[Fisher 检验,p=0.053])。两组具有显著或非常显著临床影响的干预比例相似,但由于中央验证进行的干预较少,可能有相当一部分错误未被中央验证检测到。
在病房进行药物验证可导致更高的处方错误检测率。在病房进行药物验证的药师所进行的药物干预也更易被接受,更具相关性,且不仅限于临床决策支持系统警报。